Isotope studies of uric acid metabolism during dietary purine administration.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to R Medina.
Explore the source record for details and available documents.
The effects of several doses of somatostatin (SS) and the analog Ala-2-D-Trp-8-D-Cys-14-SS on the arginine-induced release of insulin, glucagon, and GH were compared in a group of normal human subjects. Somatostatin suppressed the release of insulin, glucagon and GH when administered in a dose of 100 micrograms/hr. The same dose of Ala-2-D-Trp-8-D-Cys-14-SS inhibited GH and glucagon release, but although insulin levels were decreased about 24%, this inhibition was not significant statistically. Higher doses of Ala-2-D-Trp-8-D-Cys-14-SS (300 micrograms/hr) induced a partial inhibition of insulin secretion and completely blocked GH release. These results indicate that in humans this analog is a less potent inhibitor of insulin release than somatostatin.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Pool size, turnover, and excretion of uric acid were investigated in three normal subjects both during purine-free, isoenergetic liquid formula diet and during additional purine administration by use of isotope dilution techniques. The fractional turnover of the uric acid pool was increased during dietary purine administration suggesting an increased total body uric acid clearance as a result of the increase in renal clearance. Fractional turnover increased more in the female subject than in males, while pool size was increased less. It can be calculated from the results obtained that endogenous uric acid synthesis is not inhibited by dietary purines.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
OBJECTIVE: Fifteen-day praziquantel therapy for parenchymal neurocysticercosis has been shown to be effective. Plasma and cerebrospinal fluid concentrations of praziquantel peak two hours after administration. Maintenance of high concentrations of the drug for six hours may be an adequate therapy for the disease. METHODS: Thirty patients with parenchymal neurocysticercosis were treated with three oral doses of praziquantel(25 mg/kg) at two-hour intervals. Intramuscular dexamethasone (10 mg/day) was administered for three days after the praziquantel treatment. RESULTS: Cysts disappeared in 21 patients and showed a decrease in number of 30 to 60% in seven patients. Two patients remained without change. Considering the total number of cysts, this therapy showed a 70.7% eradication rate. Two patients had seizures, six reported headache, and nausea was frequently reported. Patients under antiepileptic treatment did not have seizures. CONCLUSION: The cost and duration of treatment with praziquantel were significantly reduced and the inflammation that follow the destruction of the parasite was treated sequentially.
The utilization of citrate by Lactobacillus casei subsp. rhamnosus ATCC 7469 in a complex medium containing glucose, lactose or citrate was investigated, as an approach to the question of the transport of this acid and the possible relationship with the production of flavour compounds (diacetyl and acetoin). This lactobacillus uses citrate as an energy source in the absence of carbohydrates. External pH and growth increases when citrate is added to complex medium. The presence of citrate does not affect glucose uptake. L. casei ATCC 7469 possibly uses a transport system for citrate utilization, and citrate uptake seems to be under glucose or lactose control. Lactose only inhibits the entrance of citrate at high concentration while the utilization of this acid was negatively regulated by low glucose concentration.